Squarepoint Ops LLC Acquires Shares of 87,989 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Squarepoint Ops LLC purchased a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 87,989 shares of the biopharmaceutical company's stock, valued at approximately $3,702,000. Squarepoint Ops LLC owned 0.10% of Ultragenyx Pharmaceutical as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth $40,463,000. Deep Track Capital LP purchased a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at about $27,493,000. Pictet Asset Management Holding SA raised its holdings in shares of Ultragenyx Pharmaceutical by 125.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock valued at $49,375,000 after acquiring an additional 653,088 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Ultragenyx Pharmaceutical by 81.0% during the 4th quarter. Point72 Asset Management L.P. now owns 1,182,877 shares of the biopharmaceutical company's stock valued at $49,764,000 after buying an additional 529,217 shares in the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of Ultragenyx Pharmaceutical by 3,097.1% during the 4th quarter. First Trust Advisors LP now owns 544,202 shares of the biopharmaceutical company's stock valued at $22,894,000 after buying an additional 527,180 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on RARE shares. JPMorgan Chase & Co. raised their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Canaccord Genuity Group raised their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. William Blair started coverage on Ultragenyx Pharmaceutical in a report on Wednesday. They set an "outperform" rating and a $65.00 price objective on the stock. Morgan Stanley lifted their price target on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $89.31.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 73,434 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the sale, the chief executive officer now directly owns 641,731 shares in the company, valued at $27,016,875.10. The trade was a 10.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Theodore Alan Huizenga sold 967 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the sale, the chief accounting officer now owns 50,265 shares in the company, valued at $2,116,156.50. This represents a 1.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 97,415 shares of company stock worth $4,094,958. 5.50% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Trading Down 3.3%

Shares of RARE stock traded down $1.16 during trading hours on Friday, reaching $33.87. The company's stock had a trading volume of 1,631,431 shares, compared to its average volume of 838,842. The stock has a market capitalization of $3.20 billion, a P/E ratio of -5.34 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a one year low of $29.59 and a one year high of $60.37. The firm's fifty day simple moving average is $35.61 and its 200 day simple moving average is $40.66.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The business had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Ultragenyx Pharmaceutical's quarterly revenue was up 28.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.03) earnings per share. As a group, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.